Abstract
As we celebrate 100 years since the first use of the bacillus Calmette-Guérin (BCG) vaccine, the only licensed vaccine against tuberculosis, this is an opportune time to examine the current state of tuberculosis vaccine development. With a better understanding of the host innate and adaptive immune response to infection and how Mycobacterium tuberculosis grows and subverts this response, vaccines are being made to accommodate use in different populations. There are a diverse range of tuberculosis vaccine formulations currently in development, with the intent of designing these vaccines to target the specific stages of infection such as prevention of infection/disease or therapeutic use as stand-alone or as an adjunct to drug treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
